Dr. Otto Yang was also interviewed today though the focus

New Post Public Reply Private Reply Replies (1) Message Board
drfreak1
853
Dr. Otto Yang was also interviewed today though the focus was on COVID-19 in general and not leronlimab.

The situation sounds critical - "people are overworked and overwhelmed"

Here is hoping leronlimab becomes more readily available where and when needed.

https://finance.yahoo.com/video/people-overwo...58144.html

Yahoo Finance Video
‘People are overworked and overwhelmed’: Doctor on the state of covid-19 in California hospitals

Thu, December 24, 2020, 12:28 PM EST

Dr. Otto Yang, Professor of Medicine and Infectious Diseases at David Geffen School of Medicine at UCLA, joins Yahoo Finance’s Julia La Roche and Adam Shapiro to discuss her thoughts on the coronavirus pandemic and the state of California as it faces another spike in cases.

Video Transcript
JULIA LA ROCHE: As the US deals with the latest surge in COVID-19 cases, California has been especially hit hard. I'd like to bring into the stream Dr. Otto Yang, Professor of Medicine and Infectious Diseases at the David Geffen School of Medicine at UCLA. Dr. Yang, thank you so much for joining us. Of course, a lot of folks were talking about California and the holiday surge there.

Can you contextualize for our viewers what is happening in California as it relates to COVID-19?

OTTO YANG: Well, we've been hit with a flood of COVID cases, far exceeding anything that we saw before. And our hospitals are basically all full.

ADAM SHAPIRO: What is this like for you personally? I mean, we can't imagine the horror of this.

OTTO YANG: I'm fortunate because I'm more of a researcher. And I spend less time on the front lines than many of my colleagues. But the full time physicians who are seeing patients day to day, and the nurses, and the respiratory therapists, and all the staff in the hospitals, I think it's-- it's a horrifying experience for them, very stressful. Staffing is the limiting factor. We have enough rooms. We have enough ventilators. But staffing, we just-- people are overworked and overwhelmed.

JULIA LA ROCHE: Dr. Yang, what do you attribute this to? Is this from the Thanksgiving holiday travel that folks were warned about not to travel at that time, and now we're starting to see that manifest itself, that timeline that had been put out there. Is that what you think this is really from?

OTTO YANG: I think that's a large factor. Yes, that and loosening of policies leading up to Thanksgiving. And I think also just people reaching fatigue in terms of following guidelines to distance and mask and protect themselves.

ADAM SHAPIRO: What are your colleagues telling you about the ability-- there are other issues that hit people medically. Do the hospitals have the room to take somebody who might, God forbid, be in cardiac arrest or other kinds of emergencies?

OTTO YANG: They, of course, have no choice but to take somebody that's in that type of dire circumstance. But there's a big trickle down effect, right. So elective surgeries or elective procedures are all being delayed to conserve space in the hospital for sick patients. So it-- you know, we saw this earlier that when the hospitals started to get a bit full, that cancers were being diagnosed later or treated later.

And I think we're going to see much of the same and patients not coming in. Because they're-- the hospitals are full, and the clinics are closed.

JULIA LA ROCHE: Dr. Yang, for folks watching, if you could share some sort of message or plea for the public, what would you say to them?

OTTO YANG: I would say to, you know, listen to-- to the people on the front lines, the physicians, and the scientists and to take this seriously. It's boggles my mind that, to this day, there are still conspiracy theories floating around and people who are denying this and saying it's just like the flu. You know, this clearly is not something to be taken lightly.

And as a society, we should not be in this situation where we don't take something seriously unless it affects us personally. We need to be thinking about this as a society. And this needs to be above politics. This needs to be independent of political beliefs or political feelings.

ADAM SHAPIRO: We're seeing now what, I guess, is the wave after the Thanksgiving mistakes that people made. And now we have people, more than a million people, traveling every day since last Thursday. How bad will this get in a couple of weeks after the Christmas holiday break?

OTTO YANG: I am afraid even to try to imagine it. But it certainly-- it seems like we're on pace for it to get much, much worse. Things have only continued to ramp up. And if the predictions about people traveling for Christmas and getting together for Christmas are accurate, we're going to see as big a wave as from Thanksgiving. And so this is really going to be a huge problem.

And I think we're going to start seeing mortality rates creep up. So, you know, each patient-- part of the reason that things have improved in terms of mortality is that doctors have gotten much better at knowing how to treat the disease. But if hospitals and the hospital staff are overwhelmed, all that's going to go out the window. And mortality rates are going to climb drastically.

JULIA LA ROCHE: You know, let's talk about maybe from what should be done to kind of help limit some of this. Do we need more travel restrictions? What kind of measures could help mitigate the situation in California?

OTTO YANG: Well, certainly leadership from above would be helpful. And that's been a weak point in dealing with this pandemic that has been especially bad in this country, unfortunately. I think, at this point, to some extent, we're on our own. And we need to exercise personal responsibility. So really, the basics have not changed. So people talk about how recommendations have flip-flopped, and the scientific data have changed. That's actually not true.

The basics about how this virus have been the same since March, in terms of what people have been saying. It's really the simple basics, right, so mask wearing as much as possible, physical distancing, trying to keep events outdoors, avoiding crowded indoor spaces, avoiding meeting with people in large groups. I mean, these are really simple basics and based on what we understand of the virus and how it's spread.

JULIA LA ROCHE: Dr. Otto Yang, Professor of Medicine and Infectious Diseases at David Geffen School of Medicine at UCLA, thank you so much for taking the time and wishing you a happy and healthy holiday season and new year.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Recent Developments in Consumer Technology and Trade Relations

Updated Category News Views 245

U.S.-China Trade Dynamics Chinese President Xi Jinping has emphasized ongoing developments in the trade relations between the U.S. and China. In a recent communication with President Donald Trump, both leaders discussed potential measures that could foster a positive trajectory for trade negotiations. Amid these discussions, reports surfaced that the U.S. is contemplating...

Continue Reading
HealthEquity Amid Allegations: An Investor's Guide to HQY

Updated Category News Views 244

Understanding the Investigation into HealthEquity, Inc. Pomerantz LLP is currently conducting a thorough investigation into the claims made by investors of HealthEquity, Inc. This action highlights potential concerns regarding the company’s business practices and the conduct of certain officers and directors. What Triggered the Investigation? The investigation centers...

Continue Reading
PetVivo AI Unveils Innovative Platform to Cut Client Costs

Updated Category News Views 147

Revolutionizing Veterinary Practices with AI PetVivo AI, Inc. is taking the veterinary world by storm with the introduction of PetVivo.ai, an innovative artificial intelligence platform aimed at transforming the pet care sector. With the pet care industry experiencing exponential growth—surpassing $150 billion—this platform promises to decrease client acquisition...

Continue Reading
Avery Dennison's Earnings Anticipation: What Investors Should Know

Updated Category News Views 126

Upcoming Earnings Report for Avery Dennison Avery Dennison (NYSE: AVY) is gearing up for a significant quarter, with expectations heightened ahead of its earnings announcement. Investors are eagerly awaiting the results, which could reveal crucial insights into the company's current performance and future direction. Analysts' Expectations Market analysts predict that...

Continue Reading
Understanding Recent Trends in HDFC Bank Ltd's Short Interest

Updated Category News Views 169

Recent Developments in HDFC Bank Ltd's Short Interest HDFC Bank Ltd (NYSE:HDB) has recently experienced a notable shift in its short interest. According to the latest information, short interest as a percentage of float has decreased by 3.23%. Currently, there are 15.25 million shares sold short, representing 0.3% of the available regular shares for trading. This change...

Continue Reading